Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 6, Issue , 2013, Pages 75-79

  Nwose, Oliseyenum M ^a   Jones, Michael R ^b  

^a DAIICHI SANKYO INC   (United States)

^b Health Care Consultant   (United States)

Author keywords

Colesevelam; Pharmacology; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; BILE ACID; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FARNESOID X RECEPTOR; FATTY ACID; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INCRETIN; INSULIN DERIVATIVE; MEGLITINIDE; METFORMIN; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TGR5 PROTEIN; UNCLASSIFIED DRUG;

ANTIDIABETIC ACTIVITY; ARTICLE; CELL FUNCTION; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIARRHEA; DRUG BINDING; FATTY ACID BLOOD LEVEL; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; GLYCOGENOLYSIS; HORMONE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; LIVER FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84890085853     PISSN: 11795514     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMed.s12590     Document Type: Article

References (38)

1. Handelsman Y, Mechanick JI, Blonde L, et al. AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17 Suppl 2:1-53.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
3. Donovan JM, Von Bergmann K, Setchell KDR, et al. Efects of colesevelam HCl on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci. 2005;50(7):1232-1238.
4. Heller DP, Burke SK, Davidson DM, Donovan JM. Absorption of colesevelam hydrochloride in healthy volunteers. Ann Pharmacother. 2002;36(3):398-403.
5. Potthof MJ, Potts A, He T, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gas-trointest Liver Physiol. 2013;304(4):G371-G380.
6. Shang Q, Saumoy M, Holst JJ, Salen G, Xu G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol. 2010;298(3):G419-G424.
7. Meissner M, Herrema H, van Dijk TH, et al. Bile acid sequestration reduces plasma glucose levels in db/db mice by increasing its metabolic clearance rate. PLoS One. 2011;6(11):e24564.
8. Prawitt J, Abdelkarim M, Stroeve JHM, et al. Farnesoid X receptor defciency improves glucose homeostasis in mouse models of obesity. Diabetes. 2011;60(7): 1861-1871.
9. Tziomalos K, Karagiannis A, Mikhailidis DP, Athyros VG. Colesevelam: a new and improved bile acid sequestrant? Curr Pharm Des. 2013;19(17):3115-3123.
10. Kahn SE. Te relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003;46(1):3-19.
11. Zierath JR, Ryder J W, Doebber T, et al. Role of skeletal muscle in thiazolidin-edione insulin sensitizer (PPARγ agonist) action. Endocrinology. 1998;139(12): 5034-5041.
12. Rigby SP, Handelsman Y, Lai Y-L, Abby SL, Tao B, Jones MR. Efects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profle in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract. 2010;16(1):53-63.
13. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid efects. Arch Intern Med. 2008;168(18):1975-1983.
14. Beysen C, Murphy EJ, Deines K, et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia. 2012;55(2):432-442.
15. Henry RR, Aroda VR, Mudaliar S, Garvey WT, Chou HS, Jones MR. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(1): 40-46.
16. Schwartz SL, Lai Y-L, Xu J, et al. Te efect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord. 2010;8(2):179-188.
17. Vega GL, Dunn FL, Grundy SM. Efect of colesevelam hydrochloride on gly-cemia and insulin sensitivity in men with the metabolic syndrome. Am J Cardiol. 2011;108(8):1129-1135.
18. Rosenstock J, Fonseca VA, Garvey W T, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010;16(4):629-640.
19. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137(9):959-965.
20. Yamauchi T, Kamon J, Waki H, et al. Te fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941-946.
21. Lam TKT, van de Werve G, Giacca A. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites. Am J Physiol Endocrinol Metab. 2003;284(2):E281-E290.
22. Berlie HD, Kalus JS, Jaber LA. Tiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract. 2007;76(2):279-289.
23. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the efect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004; 164(19):2097-2104.
24. Smushkin G, Sathananthan M, Piccinini F, et al. Te effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes. 2013;62(4):1094-1101.
25. Bennett WL, Wilson LM, Bolen S, et al. Oral diabetes medications for adults with type 2 diabetes: an update. Rockville, MD: Agency for Healthcare Policy and Research; 2011. http://efectivehealthcare.ahrq.gov/ehc/products/155/644/CER27_OralDiabetesMeds_20110623.pdf. Accessed March 18, 2013.
26. Godbout A, Chiasson JL. Who should benefit from the use of alpha-glucosidase inhibitors? Curr Diab Rep. 2007;7(5):333-339.
27. Marina AL, Utzschneider KM, Wright LA, et al. Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function. Diabetes Care. 2012;35(5):1119-1125.
28. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Efects of chenodeoxy-cholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010;8(2):159-165.
29. Ramzan Z, Dufy F, Gomez J, Fisher RS, Parkman HP. Continuous glucose monitoring in gastroparesis. Dig Dis Sci. 2011;56(9):2646-2655.
30. Davies MJ, Rayman G, Grenfell A, et al. Loss of the first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolerance. Diabet Med. 1994;11(5):432-436.
31. Salehi A, Vieira E, Gylfe E. Paradoxical stimulation of glucagon secretion by high glucose concentrations. Diabetes. 2006;55(8):2318-2323.
32. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38(4):387-395.
33. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53(5):1187-1194.
34. Edgerton DS, Johnson KMS, Neal DW, et al. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like peptide 1 infusion increases liver glucose uptake in the conscious dog. Diabetes. 2009;58(1):243-249.
35. Prigeon RL, Quddusi S, Paty B, D'Alessio DA. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic efect. Am J Physiol Endocrinol Metab. 2003;285(4):E701-E707.
36. Knauf C, Cani PD, Perrin C, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest. 2005;115(12):3554-3563.
37. Suzuki T, Oba K, Igari Y, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like peptide-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch. 2007;74(5):338-343.
38. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005;329(1):386-390.